CWNM up 13 Percent (looking amazing) what are you doing?
researchdriveninvestor Newsletter
Research Driven Investor Why RDI ~~~~~~~~~~~~~~~~~~~~~~~~~~
RDI, – Research Driven Investor, reveals penny stocks with: proven management teams, increasing market share, ballooning revenues,low debt loads, improving financial ratios and much more…
Well-run companies that have great upside potential. Often these undiscovered, undervalued, or overlooked shares can multiply dramatically in value, over short time periods.
~~~~~~~~~~~~~~~~~~~~~~~~~~
CWNM up 13 Percent! Heading North…
Can We See It Bust Through .10 Cents Are you watching CWNM It could NOT be any better for you than this….
The market is super tight, and it appears that this heavy buyside coming in could have legs to .10 cents! MULI Gains 244% Since My First Email, Then I Gave You XUII Which Gains 79%, Do I Need To Say Anymore Before I get you prepared for my new pick “Crown Marketing” ticker symbol (CWNM), I want to recap on my past performance and make sure everyone has their thinking caps on….
After I got slapped across the face like a red headed step child, I went back to my core fundamentals which put me on the map as one of the best financial newsletters in the country! FACT #1. I gave you MULI priced around .49 cents, which hit $1.69 today! (Representing 244% Gains) FACT #2. I was the very first newsletter to discover MULI. Go to google and type in MULI and you`ll see the PROOF with your very own eyes.
FACT #3. I then gave you XUII yesterday which opened around .24 cents and hit a high today of .43 cents today. (Representing 79% Gains) FACT #4. I was the VERY FIRST newsletter to cover XUII yesterday morning beating out the biggest and baddest newsletters in the industry to the punch by minutes! FACT #5. You want Proof of XUII Just go look at the time I sent it out, then look to see what time AwesomePenny Stocks, Titan, and the other sister sites sent it out. (How did I do it I have a good team, and to be very candid with you: “No one can do what I do”) Before we begin with my first draft of CWNM, please keep in mind that my past performance does not guarantee anything. However, as you dig in and get waste deep…you`ll agree we got ourselves a hot play! The `Green Rush` Is On For Marijuana Companies Changes in state marijuana laws are encouraging some cannabis-related companies to go public and cash in big time! Just recently, voters in Washington state and Colorado agreed to legalize the recreational use of marijuana for adults. And medical marijuana is currently legal in 18 states and Washington D.C.
Of course, marijuana remains illegal by federal law. But people involved in what some are calling the “green rush” are still looking at business and investment opportunities in cannabis and its production.
“Think Of This Green Rush As Another Dot.com Explosion, Only This Time You Don`t Miss Out On All Of The Profits!” And according to an investor fact sheet for Medical Marijuana Inc. (MJNA +6.55%), the current U.S. medical marijuana industry is estimated at $17 billion, with expectations it could grow up to about $29 billion by 2016.
“It was almost unthinkable 10 years ago that you would have legitimate, fully reporting to the SEC companies that were in the nature of pure plays, with positions in the medical marijuana industry,” says Sterling Scott, CEO of Los Angeles-based GrowLife Inc. (PHOT -0.71%), a consortium of companies that sells products for indoor growing.
Scott, a former federal regulatory attorney, estimates there are about 10 cannabis-related companies currently being traded as over-the-counter stocks.
Most OTCs are relatively small and often new companies that don`t yet meet the requirements to be listed or traded on exchanges like Nasdaq or the New York Stock Exchange.
“The safest position during the Gold Rush in California in the 1800s was to sell (miners) the equipment they needed to go out and explore for gold,” A Doubler in one day! A 150% romp in just three days! 200% returns in just six days! If I didn`t know better, I`d swear we were talking about biotech stocks.
Well, they aren`t biotechs – but they are real moves that have been made by real stocks within the past week and a half, and they`re all from one industry.
The marijuana trade.
Leading me to why I think CWNM can be my next home run! Crown Marketing Signs New Agreement for Medical Marijuana Financing Deal May 09, 2013 (ACCESSWIRE-TNW via COMTEX) — Crown Marketing Signs New Agreement for Medical Marijuana Financing Deal Chapel Hill, NC – Crown Marketing Inc. (otcqb:CWNM) (“CWNM” or “Crown”) announced this morning that CWNM has executed a financial services agreement with a $100 Million Dollar Fund for the purposes of assisting medical marijuana producers secure financing for their commercial real estate needs and acquisitions. Crown Marketing will carry out these operations through a wholly owned subsidiary, Joint Venture Solutions Inc. (“Company”).
Company management sees tremendous growth potential in financial services which cater to medical marijuana operations, for two independent reasons.
Firstly, 19 states have recently ended the prohibition of medical marijuana. As a result of this policy reversal, the Company expects a forthcoming sudden increase in the utilization of medical marijuana in those States. Current inefficiencies in this previously untapped market are likely to yield enormous profit margins for the relatively small number of producers who are currently active in the Medical Marijuana industry.
Secondly, although several States have lifted the ban on marijuana, the federal prohibition remains in place. This fissure between state and federal regulation has created a complex conflict of law issue that most mainstream banks and other lenders wish to avoid, for fear that they may face civil or criminal penalties for conspiring to break federal law.
The Company has entered into a memorandum of understanding with one lender who controls 100 million dollars. The MOU represents a shared willingness, by and between the Company and the lender, to provide these nascent corporations with much needed loans to finance their real estate needs.
Medical Marijuana related finance operations will likely be particularly profitable for Joint Venture Solutions because Medical Marijuana industry borrowers are unable to access the traditional avenues of purchase order, mortgage based, or other financing.
Due to the constraints on the number of servicers willing to support these industry professionals, the principals operating medical marijuana growth houses and dispensaries are willing to pay markedly above the market rate for basic financial services.
Joint Venture Solutions Inc. and the handful of other lenders willing to service this burgeoning industry stand to make outsized profit margins as a result.
About the Subsidiary:
Joint Venture Solutions, Inc. (“JVS” or “Company”) will focus on the emerging medical marijuana industry. Over the short term, the Company will deal exclusively in financing operations relating to commercial real estate in the medical marijuana industry.
Once the Company has established a secure, low-maintenance cash flow through its financing operations, it will reinvest these monies into research and development pertaining to Crown`s drug delivery technology and potential uses in the medical marijuana industry. Cannabinoids and cannabidiol, or CBD`s function similarly to THC, but without a psychotropic effect.
The Company intends to research the effect of Crown`s patented drug delivery technology on time released diffusion of CBD`s on patients with a wide array of maladies.
About The Company:
The parent of the new subsidiary, Crown Marketing`s Controlled Drug Delivery Technology (CDDT) holds patents for a novel controlled-release technology, harnessing the principles of chaos theory, precise mathematical formulas and the potentials of chemical diffusion characteristics.
The spectrum and reliability of pharmacokinetic profiles achievable with this technology is superior to currently marketed formulations. Its simple design allows for a high level of flexibility in matching chrono-therapeutic requirements. Cost-efficiencies in the commercial manufacturing process, when compared to other drug delivery technologies, may constitute its most important competitive advantage.
The objective of intelligent drug delivery design amounts to maximizing the percent of the time drug plasma levels are within the therapeutic range and avoiding patient exposure to potentially toxic (High) or sub-therapeutic (Low) levels.
Crown`s cost-effective application of controlled delivery technologies may play a major role in the expansion of the pharmaceutical, OTC and nutraceuticals industry through our ability to improve on the performance of immediate release products in a manner tangible to manufacturers and consumers.
More information can be found at: www.crowncddt.com The Most Important Factor To CWNM & Every Successful Traders Fundamentals And Plan Of Attack! CWNM closed today at .053 I anticipate a lot of attention on CWNM because of my he-ro-ic recent picks. Again, in no shape of form does this guarantee success of any future profile.
Your next step is to fully research CWNM and notice the recent highs and lows by looking at a chart. You can go to bigcharts.com Sincerely, Research Driven Investor www.ResearchDrivenInvestor.com 328 8th Avenue #322 New York City, NY 10001 As always do your own research on all profiles that I give. Penny stocks are risky, like most speculative investments. Always view the company websites and base your own opinion.
~~~~~~~~~~~~~~~~~~~~~~~~~~
Disclaimer and Safe Harbor Statement www.ResearchDrivenInvestor.com and its owners, and their affiliates, directors and officers, and immediate family members, are hereafter collectively referred to as “RDI” or “we” or “us” or “our”). RDI publishes information (the “Information”) about publicly traded companies (the “Profiled Company” or the “Profiled Companies”) which has been obtained from various sources including publicly available sources on the internet. RDI does not undertake any due diligence or investigation of the Information it obtains or publishes. You should not consider the Information published by RDI to be a true, accurate, complete or reliable. The Profiled Companies actual results and financial condition may differ materially and be completely different than that published or described in the Information. The Information is not an offer or solicitation to buy or sell securities of the Profiled Companies. You should not consider the Information to be a recommendation or indication as to when you should buy or sell securities or if you should buy or sell securities of the Profiled Companies. RDI and its officers, directors, owners and employees are not licensed as brokers, broker dealers, market makers, investment bankers, investment advisors, analysts or underwriters.
You should not consider the Information when making an investment decision of whether to buy or sell securities of any Profiled Company on RDI and you should consult with and request that your investment advisor or attorney verify any information you rely upon in making an investment decision. You should consult your financial and legal advisers before purchasing or selling the securities of any Profiled Company.
Affiliates, officers, directors and employees of RDI may own or may purchase shares of the Profiled Companies and may sell their securities at times when RDI publishes Information on the Profiled Company including when investors purchase the securities of the Profiled Companies.
RDI will not advise you prior to buying or selling the securities of the Profiled Companies does not and the Information should not be considered when making a decision to buy or sell securities of the Profiled Companies. The Information is not a solicitation or recommendation to buy, sell or hold securities and does not provide reliable information or analysis of the financial position of the Profiled Companies. All statements in the Information are subject to change without notice and are not reliable. RDI is not liable for any investment decisions by its readers. Readers should independently investigate and fully understand all risks before investing in any Profiled Company.
The owners, associates, officers, directors and/or employees and/or principals of RDI may have stock positions in the Profiled Companies obtained from purchases in the open market or in private transactions. RDI will liquidate any securities of the Profiled Companies at its discretion without notification to any party including you even it has made published positive Information about a Profiled Company. By reviewing RDI`s website you accept these terms and conditions.
Any investment in the Profiled Companies involves a high degree of risk and involves risks and uncertainties, which may result in investors losing all of their invested capital. Past performance does not guarantee future results.
The information contained herein contains “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are based upon expectations, estimates and projections at the time the statements are made and involve risks and uncertainties that could cause actual events to differ materially from those anticipated. Forward-looking statements may be identified thorough the use of words such as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should, or might occur. Any statements that express or involve predictions, expectations, beliefs, plans, projections, objectives, goals or future events or performance may be forward-looking statements. Factors that could cause actual results to differ materially include but are not limited to adverse economic conditions, intense competition, lack of meaningful research results, inadequate capital, termination of contracts or agreements, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other key personnel, and other risks detailed in public information including but not limited to reports filed with the Securities and Exchange Commission and/or OTC Markets. obtained information about some of the Profiled Companies from the OTC Markets Website at www.otcmarkets.com or from the website of the Securities and Exchange Commission, at http://www.sec.gov without charge.
Buying and Selling of Shares:
RDI may sell any shares of the Profiled Companies for less than target prices set forth in the Information and may profit by selling their securities while investors are purchasing during the same time RDI publishes the Information.
The securities of the Profiled Companies are high risk, unstable, unpredictable and illiquid. The securities of the Profiled Companies are considered in most circumstances to be penny stocks and should not be purchased by anyone who cannot sustain a complete loss of their investment. If you cannot sustain the loss of your entire investment you should not purchase securities of the Profiled Companies. If at anytime you wish to be removed from our list simply
Related posts:
- CWNM my (New Profile) Last two picks gained 318 Percent, Not to
- CWNM my (New Profile) Last two picks gained 318 Percent, Not to
- Reminder- Go Pull up CWNM before everyone else does…
- Reminder- Go Pull up CWNM before everyone else does…
- CWNM up 13 Percent (looking amazing) what are you doing?